Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Mark Heipel"'
Autor:
Cecile M Krejsa, Rick D Holly, Mark Heipel, Ken M Bannink, Rebecca Johnson, Richard Roque, Jane Heffernan, Julie Hill, Lay Chin, Felecia Wagener, Faith Shiota, Katherine Henderson, Pallavur V Sivakumar, Hong-Ping Ren, Fariba Barahmand-Pour, Don Foster, Chris Clegg, Wayne Kindsvogel, Rafael Ponce, Steven D Hughes, Kim Waggie
Publikováno v:
PLoS ONE, Vol 8, Iss 6, p e67256 (2013)
Rituximab, a monoclonal antibody targeting CD20 on B cells, is currently used to treat many subtypes of B cell lymphomas. However, treatment is not curative and response rates are variable. Recombinant interleukin-21 (rIL-21) is a cytokine that enhan
Externí odkaz:
https://doaj.org/article/75eba1524ef24901bc6062fdb1f8b56a
Autor:
Julia Piasecki, Garnet Navarro, Aditya Radhakrishnan, Melissa G Works, Uma Kavita, Yan Li, Mark Heipel, Lucrezia Colonna, Anthony Amsberry, Todd Devries, Valeria Beckett, Mirna Mujacic
Publikováno v:
Blood. 136:11-12
Background: Orva-cel is an investigational B-cell maturation antigen (BCMA)-targeted chimeric antigen receptor (CAR) T cell product genetically modified with a lentiviral vector to express a CAR construct with a unique fully human single-chain variab
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8a636a87cba03d1e2a48e52a9fc5c9e8
https://doi.org/10.1182/blood-2020-136748
https://doi.org/10.1182/blood-2020-136748
Autor:
Wayne R. Kindsvogel, Kim Waggie, Lay Chin, Felecia Wagener, Ken M. Bannink, Don Foster, Rick D. Holly, Pallavur Sivakumar, Julie Hill, Rafael Ponce, Rebecca Johnson, Richard Roque, Fariba Barahmand-pour, Steven D. Hughes, Hong-Ping Ren, Chris Clegg, Jane Heffernan, Faith Shiota, Cecile M. Krejsa, Mark Heipel, Katherine Henderson
Publikováno v:
PLoS ONE, Vol 8, Iss 6, p e67256 (2013)
PLoS ONE
PLoS ONE
Rituximab, a monoclonal antibody targeting CD20 on B cells, is currently used to treat many subtypes of B cell lymphomas. However, treatment is not curative and response rates are variable. Recombinant interleukin-21 (rIL-21) is a cytokine that enhan
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5edc301b2e8bd6913ea71dc8d7a02017
https://doi.org/10.1371/journal.pone.0067256
https://doi.org/10.1371/journal.pone.0067256
Autor:
B. Johnson, R. Holly, C. Clegg, Mark Heipel, S. Hughes, K. Bannink, Eric L. Sievers, D. Foster, P. V. Sivakumar, Wayne R. Kindsvogel
Publikováno v:
Journal of Clinical Oncology. 22:2581-2581
2581 Background: IL-21 is an IL-2 family cytokine expressed by activated CD4+ T cells. It has potent immunomodulatory activities on a number of cell types and has shown significant anti-tumor activity in preclinical animal studies. Phase I studies in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::70d704ece5b624228fbb7f4bf0c4edbf
https://doi.org/10.1200/jco.2004.22.90140.2581
https://doi.org/10.1200/jco.2004.22.90140.2581